<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Specific biochemical molecules used as potential biologic markers, including modified <z:chebi fb="0" ids="33838">nucleosides</z:chebi>, <z:chebi fb="0" ids="51349">polyamines</z:chebi>, and <z:chebi fb="0" ids="16898">pyrimidine</z:chebi> catabolic end-products, were quantitatively measured in the urine of seven patients with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> before, during, and after one or more courses of therapy </plain></SENT>
<SENT sid="1" pm="."><plain>The results of this preliminary study demonstrated that patients with this disease frequently excrete significantly increased amounts oof modified nuceleosides (considered to be derived primarily from transfer <z:chebi fb="3" ids="33697">ribonucleic acid</z:chebi>), <z:chebi fb="0" ids="51349">polyamines</z:chebi>, and <z:chebi fb="0" ids="27389">beta-aminoisobutyric acid</z:chebi> during the course of their disease </plain></SENT>
<SENT sid="2" pm="."><plain>With successful treatment and rapid destruction of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells, a concomitant rise in these molecules occurs </plain></SENT>
<SENT sid="3" pm="."><plain>Elevations were observed prior to chemotherapy and changes in levels associated with treatment or <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> appeared to correlate with disease status and to aid in assessing antitumor response </plain></SENT>
<SENT sid="4" pm="."><plain>Periodic follow-up analysis of these molecules may be helfful in appraising relapse or recurrence of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> prior to overt evidence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> by existing clincial means </plain></SENT>
</text></document>